Investegate |Sensyne Health PLC Announcements | Sensyne Health PLC: NED Appointment investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Drayson Technologies Develops Next Generation Biometric Smart Cards Powered by Freevolt Energy Harvesting
Innovate UK funded project enabled Drayson Technologies to develop Plug-n-Play reference designs of its Freevolt radio frequency energy harvesting technology, delivering 3x more power for biometric smart card applications in secure access, cryptocurrency, healthcare and finance
Drayson Technologies today announces the completion its Smart Grant project, funded by Innovate UK, the UK s innovation agency. During the 6-month project, the business received over £112,000 of funding in order to develop Plug-n-Play reference designs of its Freevolt proprietary radio frequency (RF) energy harvesting technology for smart card applications in secure access, cryptocurrency, healthcare and finance.
Real world patient database and revenues rapidly growing Sensyne poised for accelerated international growth Oxford, U.K. 27 May 2021: Sensyne Health plc (LSE: SENS) ( Sensyne or the Company ), the Clinical AI company, today announces an update on trading for the financial year ended 30 April 2021 ( FY 2021 ), and an outlook statement. UPDATE ON TRADING · Robust financial performance: FY 2021 unaudited revenues of at least £9.0 million (FY 2020: £2.1 million audited). · Strong revenue growth driven by contracts with life sciences companies, with recognition of the majority of the £4.8 million minimum revenues from MagnifEye AI technology contract with Excalibur Health Services ( Excalibur ). · Cash and cash equivalents were £23.6 million (unaudited) and excludes receipt of majority of minimum revenue payments from the Excalibur contract (FY 2020: £31.7 million au
A
Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company" or the "Group"), the Clinical AI company today announces that, together with its U.S. based strategic partner Phesi Inc. ("Phesi"), the two